阿基仑赛对比标准治疗用于二线大B细胞淋巴瘤:基于代谢肿瘤体积的结局分析
本研究为ZUMA-7三期试验的探索性分析,评估基线代谢肿瘤体积(MTV)与二线大B细胞淋巴瘤患者临床结局的关系。患者随机接受阿基仑赛或标准治疗。在高MTV和低MTV亚组中,阿基仑赛的事件无进展生存期和无进展生存期均优于标准治疗。基线MTV小于或等于中位数与更好的临床结局相关。
要点
- 在高MTV和低MTV亚组中,阿基仑赛的事件无进展生存期和无进展生存期均优于标准治疗。
- 高MTV患者的事件无进展生存期在阿基仑赛组数值上更短,在标准治疗组显著更短。
- 两个治疗组中,高MTV患者的无进展生存期均短于低MTV患者。
核心结论
- 基线MTV小于或等于中位数与接受阿基仑赛或标准治疗的二线大B细胞淋巴瘤患者更好的临床结局相关。
研究设计与样本
- ZUMA-7三期研究(NCT03391466)的探索性分析,纳入一线化学免疫治疗后12个月内复发或难治的大B细胞淋巴瘤患者,按1:1随机接受阿基仑赛或标准治疗。
主要发现
- 在高MTV和低MTV亚组中,阿基仑赛的事件无进展生存期和无进展生存期均优于标准治疗。
- 高MTV患者的事件无进展生存期在阿基仑赛组数值上更短,在标准治疗组显著更短。
- 两个治疗组中,高MTV患者的无进展生存期均短于低MTV患者。
- 数据截止时持续缓解患者的MTV中位数低于其他患者。
- 接受阿基仑赛治疗并发生≥3级神经系统事件或细胞因子释放综合征的患者,其MTV中位数分别高于发生1/2级或无神经系统事件或细胞因子释放综合征的患者。
关键数值与推荐
- MTV分类:低为小于或等于中位数,高为大于中位数。
- 标准治疗为2-3周期化学免疫治疗后,对治疗有反应的患者接受大剂量化疗联合自体造血干细胞移植。
- 所有P值均为描述性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic tumor volume (MTV) assessed using 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography, a measure of tumor burden, is a promising prognostic indicator in large B-cell lymphoma (LBCL). This exploratory analysis evaluated relationships between baseline MTV (categorized as low [median or less] vs high [greater than median]) and clinical outcomes in the phase 3 ZUMA-7 study (NCT03391466). Patients with LBCL relapsed within 12 months of or refractory to first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel (axi-cel; autologous anti-CD19 chimeric antigen receptor T-cell therapy) or standard care (2-3 cycles of chemoimmunotherapy followed by high-dose chemotherapy with autologous stem cell transplantation in patients who had a response). All P values are descriptive. Within high- and low-MTV subgroups, event-free survival (EFS) and progression-free survival (PFS) were superior with axi-cel vs standard care. EFS in patients with high MTV (vs low MTV) was numerically shorter with axi-cel and was significantly shorter with standard care. PFS was shorter in patients with high MTV vs low MTV in both the axi-cel and standard-care arms, and median MTV was lower in patients in ongoing response at data cutoff vs others. Median MTV was higher in patients treated with axi-cel who experienced grade ≥3 neurologic events or cytokine release syndrome (CRS) than in patients with grade 1/2 or no neurologic events or CRS, respectively. Baseline MTV less than or equal to median was associated with better clinical outcomes in patients receiving axi-cel or standard care for second-line LBCL. The trial was registered at www.clinicaltrials.gov as #NCT03391466.
引用
- Locke FL, Oluwole OO, Kuruvilla J, et al. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. Blood. 2024. PMID: 38557775. doi:10.1182/blood.2023021620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。